Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced its upcoming scientific presentations at two conferences in November 2022. The first presentation, at the American Heart Association Scientific Sessions on November 5, will focus on the effects of Pemvidutide (ALT-801) on lipid mediators. The second, at the American Association for the Study of Liver Disease on November 7, will present results from a Phase 1b trial evaluating a dual receptor agonist's impact on liver fat reduction in patients with non-alcoholic fatty liver disease. Presentation materials will be accessible on Altimmune's website.

Positive

• Presentation of promising results for Pemvidutide (ALT-801) at a major conference could enhance visibility.
• Data from Phase 1b trial on dual receptor agonist demonstrates potential in treating non-alcoholic fatty liver disease.

Negative

• None.

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:

• American Heart Association Scientific Sessions 2022, Chicago, IL
  Saturday, November 5, 2022
  Poster Presentation at 11:00 am Central Time
  Title: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
  Lead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women’s Hospital

• American Association for the Study of Liver Disease, The Liver Meeting^®, Washington, DC
  Monday, November 7, 2022
  Poster Presentation at 1:00 pm Eastern Time
  Title: Effects of a Balanced GLP-1/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Non-alcoholic Fatty Liver Disease
  Lead Author: Stephen A. Harrison, MD, Medical Director, Pinnacle Research

A copy of the presentation materials will be accessible on the Events section of the Altimmune website.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

What is Altimmune presenting at the American Heart Association Scientific Sessions 2022?

Altimmune will present a poster on the effects of Pemvidutide (ALT-801) on lipid mediators on November 5, 2022.

What are the details of the Phase 1b trial presented by Altimmune at the Liver Meeting?

Altimmune's presentation on November 7, 2022, focuses on a dual receptor agonist's impact on liver fat and weight loss.

When will Altimmune's presentations take place?

The presentations are scheduled for November 5 and November 7, 2022.

What is the significance of Pemvidutide in Altimmune's pipeline?

Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for obesity and NASH treatment.

How can I access Altimmune's presentation materials?

The presentation materials will be available on Altimmune's website in the Events section.